immunotherapies is a key challenge in oncology. Notably, tumor mutational burden detected by tissue next generation sequencing (NGS) was found to be correlated with response to immune checkpoint inhibitors. Methods: In this retrospective study, data were collected on NSCLC patients treated in multiple medical centers in Israel between 2014 and 2017. We used NGS on cell-free circulating tumor DNA (ctDNA) to evaluate whether mutational burden influences the response to immunotherapy in these patients. Results: Overall, 336 NSCLC patients underwent NGS on ctDNA. Of these 336 patients, 192 (57%) were females and 144 (43%) were males. The average age (range) was 64 (23-103) years. Clinical treatment information is currently available for 117 patients, of whom 50 (43%) received immune check-point inhibitors. Rates of stable disease, partial and complete responses (RECIST criteria), as well as progression-free survival and overall survival will be reported. In addition, to unravel the genomic determinants of response to immunotherapy we will use the blood-derived ctDNA to understand if hypermutated ctDNA is a predictive biomarker of response to immunotherapy. Conclusions: ctDNA collection was feasible in 336 patients. Prediction model to associate the ctDNA signature with response to immunotherapy will be presented.
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In vivo study of a novel chemoablative, thermoresponsive hydrogel for intratumoural administration in a murine A549 xenograft model S.M. Rossi, B.K. Ryan, H.M. Kelly Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland Background: Direct intratumoural (IT) injection of chemotherapeutics into solid tumours has potential to achieve high local concentrations, reducing systemic toxicity and off target side effects. However, this approach is limited by rapid drug clearance from the tumour, resulting in inaccurate and unpredictable dosing. Thermoresponsive hydrogels undergo a characteristic phase change in response to temperature. This allows for minimally invasive administration of a liquid via needle/catheter into the tumour, with localisation and retention following gelation at physiological temperatures. Drug loading of hydrogels facilitates localised, controlled delivery of chemotherapeutics to the tumour, with reduced off site toxicity. Methods: Preclinical assessment of blank and drug loaded formulations was conducted in a murine A549 xenograft model (approved by the RCSI ethics committee). 1 × 10 6 A549-luciferase cells were subcutaneously injected into the right flank of female Athymic NudeFoxn1 nu mice (n = 6 per group). At a tumour volume of approx. 250 mm 3 , 100 μL of hydrogel (blank or drug loaded) or saline was injected IT using a 22G needle. Tumour growth was assessed using callipers and an IVIS ® Spectrum in vivo imaging system over 14 days. On day 14, mice were sacrificed; tumours, liver and kidney excised, fixed and embedded in paraffin for histological and immunohistochemistry studies. Results: Two hours after IT injection, IVIS ® imaging indicated localisation and retention of the hydrogel at injection site. At day 7 and 14 following blank or drug loaded hydrogel treatment, a significant reduction in tumour growth was observed compared to saline ( p = 0.001). Retention of the hydrogel at the tumour site for up to 14 days was observed in ex vivo tumour tissue. No change in welfare scoring was observed during the study, with 100% survival at day 14, indicating treatment did not result in acute off site toxicity. Conclusions: Preliminary preclinical studies have shown the blank and drug loaded hydrogels significantly reduce tumour growth. Further studies are required to fully elucidate the underlying mechanism of action. IT administration of this formulation may represent a potential new adjuvant approach in lung cancer treatment. Legal entity responsible for the study: Royal College of Surgeons in Ireland Funding: Enterprise Ireland Disclosure: All authors have declared no conflicts of interest.
